Public Offering

Chewy, Inc. announced a major shareholder’s sale of 23.9 million shares at $41.95 with a concurrent $100 million share repurchase by the company. This move, backed by a special committee, is separate from an existing $500 million repurchase program. The transactions, expected to close by June 25, 2025, signal confidence in Chewy’s strategy within the evolving online pet market, offering an opportunity for BC Partners to realize returns.

Oklo Inc., an advanced nuclear technology firm, is launching a public offering of 6,666,667 Class A shares at $60.00 each, potentially raising $400 million. The capital will fund operations and future investments. Goldman Sachs and BofA Securities are leading the offering, expected to close June 16, 2025. Oklo aims to develop clean, reliable energy via fast fission power plants, while also focusing on radioisotope production and fuel recycling.

Insmed Incorporated announced a $750 million public offering of common stock, selling 7,812,500 shares at $96.00 each. Proceeds will fund brensocatib’s R&D, ARIKAYCE’s commercialization, and pipeline expansion. This strategic move aims to bolster financial standing and accelerate drug development across pulmonary and inflammatory conditions. The offering, led by major financial institutions, is expected to close on June 13, 2025, subject to customary conditions.

Draganfly Inc. announced the partial exercise of the over-allotment option from its recent US$3.6 million public offering. Maxim Group LLC purchased an additional 100,000 common shares at US$2.09 per share, generating US$209,000. Proceeds will fund operations, growth initiatives, product development, and potential strategic acquisitions. The offering was executed under a prior shelf registration, with securities sold exclusively in the U.S.

Helius Medical Technologies has priced its public offering, offering 2,768,600 shares of Class A common stock equivalents with warrants for an additional 2,768,600 shares at $3.27 per unit. Warrants have a 2.5-year lifespan and an initial exercise price of $7.35. The offering is expected to close June 6, 2025, with gross proceeds of $9.1 million. Maxim Group LLC is the placement agent.

Orange County Bancorp, Inc. (OBT) announced a public offering of 1,720,430 shares at $23.25 each, potentially raising $40-$46 million in gross proceeds. Funds will support general corporate purposes, including growth initiatives, capital strengthening, and potential acquisitions. The offering, managed by Piper Sandler and Stephens, is expected to close June 5, 2025. Investors should review SEC filings for details.

Super League Enterprise (SLE) announced the successful closing of an underwritten public offering on May 30, 2025, raising approximately $550,000 in gross proceeds. The offering involved the sale of common stock at $0.12 per share, including the underwriter’s overallotment option. Funds will be used for general corporate purposes, working capital, and debt repayment, supporting Super League’s mission to revolutionize brand engagement through playable media.

TAT Technologies Ltd. announced the pricing of a public offering of 4,150,000 ordinary shares at $26.00 each. The company will sell 1,625,000 shares, while FIMI Opportunity V and FIMI Israel Opportunity Five will sell 2,525,000. Underwriters have options to purchase additional shares. The offering is expected to close around June 3, 2025, generating approximately $42.3 million in gross proceeds for TAT, allocated towards general corporate needs. Stifel and Truist Securities are joint book-running managers.

Taysha Gene Therapies (TSHA) announced a public offering to raise approximately $200 million. The offering includes common stock and pre-funded warrants, priced at $2.75 and $2.749 per share respectively. This capital will advance Taysha’s CNS-focused gene therapy programs, targeting diseases like Rett syndrome with its AAV-based therapies. The deal is expected to close around May 30, 2025.

Guardian Pharmacy Services (NYSE: GRDN) priced its public offering of 7.5 million Class A shares at $21.00 each, including 6.06 million shares from existing stockholders and 1.44 million new shares. Proceeds from new shares will repurchase 1.44 million converted Class B shares, preventing net dilution. Raymond James leads underwriting with a 30-day option for 1.13 million additional shares. The SEC-approved offering, effective May 22, supports Guardian’s strategy to balance capital allocation while serving long-term care facilities in 38 states.